vs
CENTERSPACE（CSR）とNATURES SUNSHINE PRODUCTS INC（NATR）の財務データ比較。上の社名をクリックして会社を切り替えられます
NATURES SUNSHINE PRODUCTS INCの直近四半期売上が大きい（$123.8M vs $65.1M、CENTERSPACEの約1.9倍）。NATURES SUNSHINE PRODUCTS INCの純利益率が高く（3.3% vs -23.0%、差は26.3%）。NATURES SUNSHINE PRODUCTS INCの前年同期比売上増加率が高い（4.7% vs -3.0%）。過去8四半期でNATURES SUNSHINE PRODUCTS INCの売上複合成長率が高い（5.6% vs 0.0%）
Centerspaceは高品質な集合住宅の所有、運営、開発を主力事業とする不動産投資企業です。主な事業エリアは米国中西部とロッキー山脈西部で、多様な入居者層に手頃な住宅から高級住宅までを提供し、入居者体験と資産の長期的価値向上を重視しています。
Natures Sunshine Products, Inc.（通称NSP）は、ハーブ、ビタミン、ミネラルを含む栄養補助食品やスキンケアなどのパーソナルケア製品の製造を行っています。本社はユタ州リーハイに置き、同州スパニッシュフォークに生産拠点を構えています。
CSR vs NATR — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $123.8M |
| 純利益 | $-15.0M | $4.1M |
| 粗利率 | — | 72.5% |
| 営業利益率 | — | 4.3% |
| 純利益率 | -23.0% | 3.3% |
| 売上前年比 | -3.0% | 4.7% |
| 純利益前年比 | -258.1% | 1379.4% |
| EPS（希薄化後） | $-0.49 | $0.23 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $65.1M | — | ||
| Q4 25 | $66.6M | $123.8M | ||
| Q3 25 | $71.4M | $128.3M | ||
| Q2 25 | $68.5M | $114.8M | ||
| Q1 25 | $67.1M | $113.2M | ||
| Q4 24 | $66.4M | $118.2M | ||
| Q3 24 | $65.0M | $114.6M | ||
| Q2 24 | $65.0M | $110.6M |
| Q1 26 | $-15.0M | — | ||
| Q4 25 | $-18.4M | $4.1M | ||
| Q3 25 | $53.8M | $5.3M | ||
| Q2 25 | $-14.5M | $5.3M | ||
| Q1 25 | $-3.7M | $4.7M | ||
| Q4 24 | $-5.1M | $-321.0K | ||
| Q3 24 | $-1.0M | $4.3M | ||
| Q2 24 | $-1.3M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | 96.5% | 72.5% | ||
| Q3 25 | 96.5% | 73.3% | ||
| Q2 25 | 96.5% | 71.7% | ||
| Q1 25 | 96.4% | 72.1% | ||
| Q4 24 | 96.5% | 72.0% | ||
| Q3 24 | 96.6% | 71.3% | ||
| Q2 24 | 96.6% | 71.4% |
| Q1 26 | — | — | ||
| Q4 25 | -15.9% | 4.3% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | -9.9% | 3.7% | ||
| Q1 25 | 7.1% | 5.4% | ||
| Q4 24 | 4.3% | 3.8% | ||
| Q3 24 | 9.8% | 4.6% | ||
| Q2 24 | 11.1% | 5.1% |
| Q1 26 | -23.0% | — | ||
| Q4 25 | -27.7% | 3.3% | ||
| Q3 25 | 75.3% | 4.2% | ||
| Q2 25 | -21.2% | 4.6% | ||
| Q1 25 | -5.6% | 4.2% | ||
| Q4 24 | -7.6% | -0.3% | ||
| Q3 24 | -1.6% | 3.8% | ||
| Q2 24 | -2.0% | 1.2% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-1.08 | $0.23 | ||
| Q3 25 | $3.19 | $0.30 | ||
| Q2 25 | $-0.87 | $0.28 | ||
| Q1 25 | $-0.22 | $0.25 | ||
| Q4 24 | $-0.31 | $-0.02 | ||
| Q3 24 | $-0.40 | $0.23 | ||
| Q2 24 | $-0.19 | $0.07 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $7.6M | $93.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $695.0M | $161.6M |
| 総資産 | $1.9B | $261.1M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $7.6M | — | ||
| Q4 25 | $12.8M | $93.9M | ||
| Q3 25 | $12.9M | $95.6M | ||
| Q2 25 | $12.4M | $81.3M | ||
| Q1 25 | $11.9M | $86.5M | ||
| Q4 24 | $12.0M | $84.7M | ||
| Q3 24 | $14.5M | $78.7M | ||
| Q2 24 | $14.3M | $68.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $955.5M | — | ||
| Q4 24 | $955.4M | — | ||
| Q3 24 | $921.3M | — | ||
| Q2 24 | $931.7M | — |
| Q1 26 | $695.0M | — | ||
| Q4 25 | $719.2M | $161.6M | ||
| Q3 25 | $748.6M | $166.7M | ||
| Q2 25 | $710.1M | $163.7M | ||
| Q1 25 | $636.8M | $167.1M | ||
| Q4 24 | $752.0M | $161.0M | ||
| Q3 24 | $672.5M | $162.6M | ||
| Q2 24 | $680.7M | $156.4M |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.9B | $261.1M | ||
| Q3 25 | $2.1B | $264.8M | ||
| Q2 25 | $2.0B | $254.9M | ||
| Q1 25 | $1.9B | $252.7M | ||
| Q4 24 | $1.9B | $240.9M | ||
| Q3 24 | $1.9B | $245.3M | ||
| Q2 24 | $1.9B | $235.8M |
| Q1 26 | — | — | ||
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.37× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $9.9M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $7.6M |
| FCFマージンFCF / 売上 | — | 6.1% |
| 設備投資強度設備投資 / 売上 | 0.3% | 1.9% |
| キャッシュ転換率営業CF / 純利益 | — | 2.41× |
| 直近12ヶ月FCF直近4四半期 | — | $28.8M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $98.5M | $9.9M | ||
| Q3 25 | $35.1M | $18.5M | ||
| Q2 25 | $25.3M | $4.3M | ||
| Q1 25 | $25.4M | $2.6M | ||
| Q4 24 | $98.2M | $12.2M | ||
| Q3 24 | $32.3M | $9.6M | ||
| Q2 24 | $22.9M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | $64.3M | $7.6M | ||
| Q3 25 | $25.7M | $16.8M | ||
| Q2 25 | $15.5M | $3.0M | ||
| Q1 25 | $20.4M | $1.5M | ||
| Q4 24 | $41.6M | $10.0M | ||
| Q3 24 | $20.5M | $7.9M | ||
| Q2 24 | $9.1M | $-2.0M |
| Q1 26 | — | — | ||
| Q4 25 | 96.5% | 6.1% | ||
| Q3 25 | 36.0% | 13.1% | ||
| Q2 25 | 22.7% | 2.6% | ||
| Q1 25 | 30.4% | 1.3% | ||
| Q4 24 | 62.6% | 8.5% | ||
| Q3 24 | 31.5% | 6.9% | ||
| Q2 24 | 14.0% | -1.9% |
| Q1 26 | 0.3% | — | ||
| Q4 25 | 51.3% | 1.9% | ||
| Q3 25 | 13.1% | 1.3% | ||
| Q2 25 | 14.2% | 1.2% | ||
| Q1 25 | 7.5% | 1.0% | ||
| Q4 24 | 85.3% | 1.9% | ||
| Q3 24 | 18.2% | 1.5% | ||
| Q2 24 | 21.2% | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.41× | ||
| Q3 25 | 0.65× | 3.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | — | 0.97× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSR
セグメントデータなし
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
